October 31 (SeeNews) - Bulgarian medical consumables producer Etropal [BUL:ETR] said that it booked a standalone net profit of 376,000 levs ($203,877/192,245 euro) in the first nine months of this year against a net loss of 456,000 levs in the comparable period of 2022, on the back of higher revenue.
Operating revenue more than doubled to 7.6 million levs in January-September from 3.6 million levs in the prior-year period, the company said in an interim financial statement on Monday. Revenue from product sales surged to 5.5 million levs in the review period from 1.9 million levs a year earlier.
Etropal's expenses jumped to 7.2 million levs from 4.1 million levs, mainly driven by costs for materials, which went up to 3.5 million levs from 1.6 million levs.
The company's assets grew to 18.14 million levs at the end of September from 17.27 million levs at the end of last year.
Etropal specialises mainly in the production of consumables for hemodialysis.
Shares in Etropal last traded on October 30 when they closed at 5.00 levs on the Bulgarian Stock Exchange, bourse data show.
(1 euro = 1.95583 levs)